Jin KT - Search Results

1

Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.

Lan HR, Chen M, Yao SY, Chen JX, Jin KT. Lan HR, et al. Among authors: jin kt. Front Immunol. 2023 Dec 4;14:1266450. doi: 10.3389/fimmu.2023.1266450. eCollection 2023. Front Immunol. 2023. PMID: 38111570 Free PMC article. Review.

2

Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it.

Jin K, Lan H, Zhu T, He K, Teng L. Jin K, et al. Clin Transl Oncol. 2011 Jan;13(1):25-33. doi: 10.1007/s12094-011-0613-1. Clin Transl Oncol. 2011. PMID: 21239352 Review.

3

Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?

Li Z, Jin K, Lan H, Teng L. Li Z, et al. Hepatogastroenterology. 2011 Mar-Apr;58(106):411-6. Hepatogastroenterology. 2011. PMID: 21661405 Review.

4

Surgical management of retrorectal tumors: a retrospective study of a 9-year experience in a single institution.

Lin C, Jin K, Lan H, Teng L, Lin J, Chen W. Lin C, et al. Onco Targets Ther. 2011;4:203-8. doi: 10.2147/OTT.S25271. Epub 2011 Nov 30. Onco Targets Ther. 2011. PMID: 22162926 Free PMC article.

5

Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases.

Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, Xu Z, Teng L, Zhu T. Jin K, et al. PLoS One. 2011;6(12):e28384. doi: 10.1371/journal.pone.0028384. Epub 2011 Dec 2. PLoS One. 2011. PMID: 22164281 Free PMC article.

6

Estrogen-independent effects of ER-α36 in ER-negative breast cancer.

Zhang J, Li G, Li Z, Yu X, Zheng Y, Jin K, Wang H, Gong Y, Sun X, Teng X, Cao J, Teng L. Zhang J, et al. Steroids. 2012 May;77(6):666-73. doi: 10.1016/j.steroids.2012.02.013. Epub 2012 Feb 27. Steroids. 2012. PMID: 22402113

7

Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.

Dong X, Jin K, Hu X, Du F, Lan H, Han N, Ma Z, Xie B, Cui B, Teng L, Cao F. Dong X, et al. Int J Mol Med. 2012 Jul;30(1):126-32. doi: 10.3892/ijmm.2012.968. Epub 2012 Apr 10. Int J Mol Med. 2012. PMID: 22505231

8

FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.

Gao W, Jin K, Lan H, Han N, Cao F, Teng L. Gao W, et al. Hepatogastroenterology. 2012 Nov-Dec;59(120):2543-7. doi: 10.5754/hge12159. Hepatogastroenterology. 2012. PMID: 22534543

9

Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.

Jin K, Lan H, Cao F, Han N, Xu Z, Li G, He K, Teng L. Jin K, et al. Int J Oncol. 2012 Aug;41(2):583-8. doi: 10.3892/ijo.2012.1469. Epub 2012 May 10. Int J Oncol. 2012. PMID: 22581265

10

Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.

Jin K, Lan H, Xie B, He K, Xu Z, Li G, Han N, Teng L, Cao F. Jin K, et al. Cancer Biol Ther. 2012 Jul;13(9):737-44. doi: 10.4161/cbt.20556. Epub 2012 May 23. Cancer Biol Ther. 2012. PMID: 22617773 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters